SCHEMBL5538227

SCHEMBL5538227

CCOC(=O)C1CCN(c2ccc(-c3nc(C#N)c(C)nc3C)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
ALDH1A1 P00352 7/20 0.50
KDM4E B2RXH2 7/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
LMNA P02545 1/20 0.50
LGMN Q99538 2/20 0.48
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LCK P06239 1/20 0.46
JAK3 P52333 1/20 0.46
RET P07949 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5532095 0.88 KDM4E (0.58) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5538159 0.88 KDM4E (0.58) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5535294 0.87 ALDH1A1 (0.38) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL13769245 0.84 LGMN (0.56) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5533302 0.82 CETP (0.41) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5536327 0.81 DGAT1 (0.37) ALDH1A1KDM4EKMT2AGAAHPGD
SCHEMBL2654128 0.79 MAPT (0.64) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5533315 0.75 KDM4D (0.36) KMT2AJAK3
SCHEMBL2259355 0.75 USP14 (0.38) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL27543 0.75 LGMN (0.70) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234978-B1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 ASTRAZENECA AB (SE) 2015-02-25 EP disclosed
US-20120108602-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2012-05-03 US disclosed
US-20120108602-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2012-05-03 US disclosed
US-7994179-B2 Carbamoyl compounds as DGAT1 inhibitors 190 ASTRAZENECA AB (SE) 2011-08-09 US disclosed
US-7994179-B2 Carbamoyl compounds as DGAT1 inhibitors 190 ASTRAZENECA AB (SE) 2011-08-09 US disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 US disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108602-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 DGAT1, DGAT2, SOAT1 MAPT 3037/4885ALDH1A1 277/4885KDM4E 2106/4885
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 DGAT1, DGAT2, SOAT1 MAPT 2909/4885ALDH1A1 272/4885KDM4E 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.